JP2016540045A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540045A5
JP2016540045A5 JP2016554526A JP2016554526A JP2016540045A5 JP 2016540045 A5 JP2016540045 A5 JP 2016540045A5 JP 2016554526 A JP2016554526 A JP 2016554526A JP 2016554526 A JP2016554526 A JP 2016554526A JP 2016540045 A5 JP2016540045 A5 JP 2016540045A5
Authority
JP
Japan
Prior art keywords
benzoic acid
ethynyl
phenylethynyl
pyrrol
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554526A
Other languages
English (en)
Japanese (ja)
Other versions
JP6744218B2 (ja
JP2016540045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065765 external-priority patent/WO2015073864A1/en
Publication of JP2016540045A publication Critical patent/JP2016540045A/ja
Publication of JP2016540045A5 publication Critical patent/JP2016540045A5/ja
Application granted granted Critical
Publication of JP6744218B2 publication Critical patent/JP6744218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554526A 2013-11-15 2014-11-14 Ｅｂｎａ１阻害剤およびそれらの使用方法 Active JP6744218B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904555P 2013-11-15 2013-11-15
US61/904,555 2013-11-15
PCT/US2014/065765 WO2015073864A1 (en) 2013-11-15 2014-11-14 Ebna1 inhibitors and their method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020129107A Division JP2020196723A (ja) 2013-11-15 2020-07-30 Ｅｂｎａ１阻害剤およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2016540045A JP2016540045A (ja) 2016-12-22
JP2016540045A5 true JP2016540045A5 (enExample) 2017-11-30
JP6744218B2 JP6744218B2 (ja) 2020-08-19

Family

ID=53058091

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016554526A Active JP6744218B2 (ja) 2013-11-15 2014-11-14 Ｅｂｎａ１阻害剤およびそれらの使用方法
JP2020129107A Withdrawn JP2020196723A (ja) 2013-11-15 2020-07-30 Ｅｂｎａ１阻害剤およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020129107A Withdrawn JP2020196723A (ja) 2013-11-15 2020-07-30 Ｅｂｎａ１阻害剤およびそれらの使用方法

Country Status (10)

Country Link
US (4) US9856214B2 (enExample)
EP (1) EP3068758B1 (enExample)
JP (2) JP6744218B2 (enExample)
KR (1) KR20160110357A (enExample)
CN (1) CN105934425B (enExample)
AU (2) AU2014348422B2 (enExample)
BR (1) BR112016011079A2 (enExample)
CA (1) CA2930584A1 (enExample)
MX (1) MX2016006325A (enExample)
WO (1) WO2015073864A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6744218B2 (ja) 2013-11-15 2020-08-19 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ｅｂｎａ１阻害剤およびそれらの使用方法
KR102616818B1 (ko) * 2015-05-14 2023-12-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Ebna1 억제제 및 그의 사용 방법
WO2017100819A1 (en) * 2015-12-14 2017-06-22 The Australian National University Modular syntheses of discoipyrrole type alkaloids and analogues
US11046731B2 (en) * 2018-01-18 2021-06-29 Hong Kong Baptist University Zinc-binder based EBNA1-specific compounds
AU2019263176B2 (en) * 2018-04-30 2025-02-27 The Trustees Of Indiana University Compounds for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease
WO2019222470A1 (en) 2018-05-17 2019-11-21 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN113754541B (zh) * 2020-06-02 2025-01-03 深圳湾实验室 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
CN116135850A (zh) * 2021-11-16 2023-05-19 深圳湾实验室 抗鼻咽癌的小分子抑制剂、化合物的制备方法及其应用
WO2024050408A1 (en) * 2022-08-30 2024-03-07 The Wistar Institute Of Anatomy And Biology Development of a novel ebna-1 degrader targeting through mdm2
CN117586230B (zh) * 2023-10-20 2024-09-24 南方医科大学深圳医院 降解ebna1的protac化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
HU190007B (en) * 1982-05-06 1986-08-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing new aromatic prostacylin analogues
DE3936297A1 (de) 1989-11-01 1991-05-02 Bayer Ag Verfahren zur herstellung von symmetrischen diarylacetylenen
DE4039448A1 (de) 1990-12-11 1992-06-17 Rhein Chemie Rheinau Gmbh Polyurethan-katalysatoren
US5356919A (en) * 1991-05-30 1994-10-18 G. D. Searle & Co. Leukotriene B4 synthesis inhibitors
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) * 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
KR100858642B1 (ko) 2000-05-22 2008-09-17 아벤티스 파마슈티칼스 인크. 트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체
CN1324012C (zh) 2000-05-31 2007-07-04 参天制药株式会社 TNF－α生成抑制剂
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20040044041A1 (en) * 2002-08-06 2004-03-04 Kuduk Scott D. 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
US7361743B2 (en) 2004-02-11 2008-04-22 Pfizer Inc Lincomycin derivatives possessing antibacterial activity
CN1288117C (zh) 2004-04-02 2006-12-06 中国科学院上海有机化学研究所 端基炔烃和芳基卤化物的偶联反应
NZ551974A (en) * 2004-07-02 2010-01-29 Inst Medical W & E Hall Alpha-helical minetics
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
MX2007001431A (es) 2004-08-05 2007-04-02 Hoffmann La Roche Derivados de indol, de indazol o de indolina.
CA2607882A1 (en) * 2005-05-12 2006-11-23 Wyeth Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
WO2007002433A1 (en) * 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2007002587A2 (en) 2005-06-24 2007-01-04 The Brigham And Women's Hospital, Inc. Inhibitors of epstein barr virus nuclear antigen 1
WO2007023242A1 (en) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
EP2049493B1 (en) 2006-07-31 2012-03-21 Cadila Healthcare Limited Compounds suitable as modulators of hdl
US7956216B2 (en) * 2006-12-21 2011-06-07 The Walter And Eliza Hall Institute Of Medical Research Alpha-helical mimetics
NZ592993A (en) 2008-10-22 2013-02-22 Acucela Inc Compounds for treating ophthalmic diseases and disorders
US8273769B2 (en) 2009-02-12 2012-09-25 Merck Serono Sa Phenoxy acetic acid derivatives
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
WO2010127440A1 (en) 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011082098A1 (en) 2009-12-30 2011-07-07 The Rockefeller University Lysine and arginine methyltransferase inhibitors for treating cancer
CA2788363A1 (en) * 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EA024194B8 (ru) * 2011-01-21 2016-11-30 Сан Фарма Адвансед Ресьорч Компани Лтд Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
US9309212B2 (en) 2011-05-24 2016-04-12 The Wistar Institute Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
WO2014145022A1 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
JP6744218B2 (ja) * 2013-11-15 2020-08-19 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ｅｂｎａ１阻害剤およびそれらの使用方法

Similar Documents

Publication Publication Date Title
JP2016540045A5 (enExample)
JP6461263B2 (ja) Ｃ−ｆｍｓおよび／またはｃ−ｋｉｔ活性を調節する化合物およびその用途
US9771369B2 (en) Compounds and methods for kinase modulation, and indications therefor
JP2012525431A5 (enExample)
RU2288227C2 (ru) Производные пиримидина, фармацевтическая композиция, способ ингибирования и применение
TWI617552B (zh) 用於激酶調節及其適應症之化合物及方法
AU2005216904B2 (en) Modulation of inflammatory and metastatic processes
JP5808793B2 (ja) キナーゼ調節のための化合物および方法、ならびにそれらの適応症
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
JP2009541311A5 (enExample)
RU2013123274A (ru) Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы
CN104981247A (zh) 用于激酶调节的化合物和方法及其适应症
JP2006514110A5 (enExample)
CA2451678A1 (en) Azaindoles
JP2012528178A5 (enExample)
KR20170039275A (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
JP2016512825A5 (enExample)
RU2010137114A (ru) Амидные производные как позитивные аллостерические модуляторы и способы их применения
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
KR20100046189A (ko) 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
RU2015148926A (ru) Аза-оксо-индолы для лечения и профилактики респираторно-синцитиальной вирусной инфекции
JP2014527529A5 (enExample)
RU2012155712A (ru) Новые производные пиримидина
AU2019202905A1 (en) EBNA1 inhibitors and their method of use
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung